Thaju Salam, MD
Cardiovascular Disease · Merriam, KSNPI 1295794733
Payments from drug & device makers
Across 441 payments — averaging $23.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Amgen$1K
- Actelion Pharmaceuticals US, Inc.$929
- Boston Scientific$861
- Pfizer$626
- Novartis$586
- plus $4K from 30 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 41 | $2,068 |
| Amgen | 65 | $1,183 |
| Actelion Pharmaceuticals US, Inc. | 30 | $929 |
| Boston Scientific | 28 | $861 |
| Pfizer | 33 | $626 |
| Novartis | 38 | $586 |
| Novo Nordisk | 28 | $578 |
| Abbott | 8 | $495 |
| Merck | 18 | $317 |
| AstraZeneca | 19 | $316 |
| Irhythm Technologies, Inc. | 10 | $279 |
| E.r. Squibb & Sons, L.L.C. | 17 | $273 |
| Amarin Pharma, Inc. | 16 | $269 |
| Sanofi-aventis U.S. LLC | 12 | $235 |
| Boehringer Ingelheim | 16 | $233 |
| Johnson & Johnson | 11 | $154 |
| Biotronik Inc. | 6 | $154 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $137 |
| Alnylam Pharmaceuticals Inc. | 6 | $100 |
| Lundbeck LLC | 5 | $79 |
| Lantheus Medical Imaging, Inc. | 4 | $77 |
| Bayer | 3 | $76 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $72 |
| Impulse Dynamics (USA) Inc. | 2 | $58 |
| Daiichi Sankyo Inc. | 2 | $50 |
| Philips North America LLC | 2 | $45 |
| Regeneron Healthcare Solutions, Inc. | 2 | $41 |
| Bridgebio Pharma, Inc. | 2 | $39 |
| Kestra Medical Technology Services, Inc. | 1 | $36 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| Gilead | 2 | $25 |
| Penumbra, Inc. | 2 | $24 |
| Atricure, Inc. | 1 | $21 |
| Ionis Pharmaceuticals, Inc. | 1 | $21 |
| Cardiva Medical, Inc. | 1 | $20 |
| Terumo Medical Corporation | 1 | $15 |
How this compares
$10,521 in reported general payments places this provider in the 80th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Merriam
- Andrew WatersMerriam$12K
- Mazda BiriaMerriam$10K
- Michelle DewMerriam$9K
- Bassem ChehabWichita$5.9M
- Wassim ShaheenWichita$1M
- Aziz MaksoudWichita$847K
- Stephen BloomOverland Park$766K
- Vasvi SinghOverland Park$436K
- Lloyd StahlOverland Park$275K
- Thomas AshcomWichita$193K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.